Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 1

Cannabinoids in the management of difficult to treat pain

Authors Ethan B Russo

Published 8 February 2008 Volume 2008:4(1) Pages 245—259

DOI http://dx.doi.org/10.2147/TCRM.S1928

Ethan B Russo

GW Pharmaceuticals, Vashon, WA, USA

Abstract: This article reviews recent research on cannabinoid analgesia via the endocannabinoid system and non-receptor mechanisms, as well as randomized clinical trials employing cannabinoids in pain treatment. Tetrahydrocannabinol (THC, Marinol®) and nabilone (Cesamet®) are currently approved in the United States and other countries, but not for pain indications. Other synthetic cannabinoids, such as ajulemic acid, are in development. Crude herbal cannabis remains illegal in most jurisdictions but is also under investigation. Sativex®, a cannabis derived oromucosal spray containing equal proportions of THC (partial CB1 receptor agonist) and cannabidiol (CBD, a non-euphoriant, anti-inflammatory analgesic with CB1 receptor antagonist and endocannabinoid modulating effects) was approved in Canada in 2005 for treatment of central neuropathic pain in multiple sclerosis, and in 2007 for intractable cancer pain. Numerous randomized clinical trials have demonstrated safety and efficacy for Sativex in central and peripheral neuropathic pain, rheumatoid arthritis and cancer pain. An Investigational New Drug application to conduct advanced clinical trials for cancer pain was approved by the US FDA in January 2006. Cannabinoid analgesics have generally been well tolerated in clinical trials with acceptable adverse event profiles. Their adjunctive addition to the pharmacological armamentarium for treatment of pain shows great promise.

Keywords: cannabinoids, tetrahydrocannabinol, cannabidiol, analgesia, pain management, multiple sclerosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy

Mischel G Neill, Rohan Shahani, Alexandre R Zlotta

Therapeutics and Clinical Risk Management 2008, 4:11-18

Published Date: 8 February 2008

Critical appraisal of medical devices in the management of cerebrovascular disease

Michael J Schneck

Therapeutics and Clinical Risk Management 2008, 4:19-29

Published Date: 8 February 2008

Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review

Jason W Bennett, James S Lewis II, Michael W Ellis

Therapeutics and Clinical Risk Management 2008, 4:31-40

Published Date: 8 February 2008

Serotonin receptor modulators in the treatment of irritable bowel syndrome

Mohammad Fayyaz, Jeffrey M Lackner

Therapeutics and Clinical Risk Management 2008, 4:41-48

Published Date: 8 February 2008

Why does the world need another rotavirus vaccine?

Richard L Ward, Monica M McNeal, A Duncan Steele

Therapeutics and Clinical Risk Management 2008, 4:49-63

Published Date: 8 February 2008

Long-term safety of aromatase inhibitors in the treatment of breast cancer

Jean-Marc A Nabholtz

Therapeutics and Clinical Risk Management 2008, 4:189-204

Published Date: 8 February 2008

Trabectedin and its potential in the treatment of soft tissue sarcoma

Philippe A Cassier, Armelle Dufresne, Jean-Yves Blay, Jérôme Fayette

Therapeutics and Clinical Risk Management 2008, 4:109-116

Published Date: 8 February 2008

A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting

Mark A Ware, Paul Daeninck, Vincent Maida

Therapeutics and Clinical Risk Management 2008, 4:99-107

Published Date: 8 February 2008